Company Filing History:
Years Active: 1998
Title: Innovations of Sungzong Kang in Antitumor Research
Introduction
Sungzong Kang is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antitumor therapies. His work focuses on enhancing the efficacy and safety of tumor necrosis factor (TNF) treatments.
Latest Patents
Sungzong Kang holds a patent for "Tumor necrosis factor muteins." This patent describes muteins of human tumor necrosis factor (hTNF), a process for their production, and the DNAs encoding these muteins. These innovations have been found to exhibit superior antitumor activity and lower acute lethal toxicity compared to the wild-type human tumor necrosis factor. He has 1 patent to his name.
Career Highlights
Kang is currently associated with Hanil Synthetic Fiber Co., Ltd., where he applies his expertise in biotechnology to develop innovative solutions. His work has garnered attention for its potential impact on cancer treatment.
Collaborations
Some of his notable coworkers include Hang-Cheol Shin and Nam-Kyu Shin. Their collaborative efforts contribute to the advancement of research in the field of tumor necrosis factors.
Conclusion
Sungzong Kang's innovative work in the development of tumor necrosis factor muteins represents a significant advancement in antitumor therapies. His contributions are paving the way for more effective cancer treatments.